Tuesday, June 30, 2015

Top 5 Diversified Bank Stocks To Own Right Now

Top 5 Diversified Bank Stocks To Own Right Now: ProShares Trust II (YCS)

ProShares Trust II (the Trust) is a statutory trust organized into separate series. The Trust offers seven Funds. The Trust offers beneficial interest in each of its 24 series. The 24 separate series include ProShares Ultra DJ-UBS Commodity, ProShares UltraShort DJ-UBS Commodity, ProShares Ultra DJ-UBS Crude Oil, ProShares UltraShort DJ-UBS Crude Oil, ProShares Ultra DJ-UBS Natural Gas, ProShares Short DJ-UBS Natural Gas, ProShares UltraShort DJ-UBS Natural Gas, ProShares Short Gold, ProShares Ultra Gold, ProShares UltraShort Gold, ProShares Ultra Silver, ProShares UltraShort Silver, ProShares Ultra Euro, ProShares UltraShort Euro, ProShares Ultra Yen ProShares UltraShort Yen, ProShares Ultra VIX Short-Term Futures ETF, ProShares VIX Short-Term Futures ETF, ProShares Short VIX Short-Term Futures ETF, ProShares UltraShort VIX Short-Term Futures ETF, ProShares Ultra VIX Mid-Term Futures ETF, ProShares VIX Mid-Term Futures ETF, ProShares Short VIX Mid-Term Futures ETF and Pro Shares UltraShort VIX Mid-Term Futures ETF.

The Funds offer investors the opportunity to obtain leveraged, inverse or inverse leveraged exposure to a particular benchmark. The Funds include funds linked to futures-based commodity indexes (the Commodity Index Funds), particular commodities (the Commodity Funds) or particular currencies (the Currency Funds). ProShare Capital Management LLC serves as the Trusts Sponsor, commodity pool operator and commodity trading advisor. Wilmington Trust Company is the sole Trustee of the Trust.

Dow Jones-UBS Commodity Index

ProShares Ultra DJ-UBS Commodity and ProShares UltraShort DJ-UBS Commodity are designed to track a multiple or an inverse multiple of the daily performance of the Dow Jones-UBS Commodity IndexSM. The Dow Jones-UBS Commodity IndexSM (the Dow Jones-UBS) is designed to be a highly liquid and diversified benchmark for the commodity futures market. It focuses to! reflect the overall c ommodity sector by measuring the performance of commodity fu! tures contracts. The Dow Jones-UBS is a rolling index, which means that the Dow Jones-UBS does not take actual physical possession of any commodities; rather, it tracks a rolling futures position. An investor with a rolling futures position is able to avoid delivering (or taking delivery of) underlying physical commodities while maintaining exposure to those commodities. The roll for each Index component occurs over a period of five Dow Jones-UBS business days in certain months according to a pre-determined schedule. The exact roll methodology differs between certain commodities. The Index will reflect the performance of its underlying commodities, including roll costs, without regard to income earned on cash positions. The Dow Jones-UBS is consisted of eight different commodity sectors, such as petroleum, natural gas, livestock, grains, industrial metals, precious metals, softs and vegetable oils. These eight sectors track futures contracts prices of 19 specific commodities , such as natural gas, crude oil, unleaded gasoline, heating oil, live cattle, lean hogs, wheat, corn, soybeans, soybean oil, aluminum, copper, zinc, nickel, gold, silver, sugar, cotton and coffee. The Dow Jones-UBS is consisted of commodities traded on the United States exchanges, with the exception of aluminum, nickel and zinc, which trade on the London Metal Exchange.

Dow Jones-UBS Natural Gas Subindex

ProShares Ultra DJ-UBS Natural Gas and ProShares UltraShort DJ-UBS Natural Gas are designed to track twice (2x) or twice the inverse (-2x) of the daily performance of the Dow Jones-UBS Natural Gas SubindexSM, respectively The Dow Jones-UBS Natural Gas SubindexSM is intended to reflect the performance of a rolling position in natural gas futures contracts traded on the NYMEX without regard to income earned on cash positions. An investment in natural gas futures contracts may often perform very differently than the price ! of physic! al natural gas.

Advisors' Opinion:
  • [By Matthew McCall]

    An ETF that takes advantage of a weak yen is the ProShares UltraShort Yen ETF (NYSE: YCS). The ETF returns two times the daily inverse of the value of the yen. For example, if the yen declines by 0.5 percent, theoretically YCS should be up 1.0 percent and vice versa. The leveraged aspect of the ETF makes it too risky for most investors and it should only be considered a short-term trading vehicle.

  • [By Ben Levisohn]

    The euro has dropped about 0.8% against the dollar, while the CurrencyShares Euro Trust ETF (FXE) has dropped 0.7% to $136.71 and the Currency Shares Japanese Yen Trust ETF (FXY) has fallen 1%. The ProShares UltrasShort Euro ETF (EUO) has gained 1.3% to $16.77, while the ProShares UltraShort Yen (YCS) has gained 1.9% to $66.58.

  • [By Anthony Mirhaydari]

    Today, the yen carry trade, as represented by the ProShares UltraShort Yen (YCS) , is collapsing below both its lower Bollinger Band and its 50-day moving average the most significant downtrend initiation since June. The scramble to cover positions funded by yen carry trades is why the selling is so frantic.

  • [By MONEYMORNING]

    Split your capital in two halves. With one half, buy ProShares UltraShort Yen (NYSE Arca: YCS), and with other half, buy shares of AMLP, simple and clean.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-diversified-bank-stocks-to-own-right-now.html

Monday, June 29, 2015

Top 10 Performing Companies To Watch In Right Now

Top 10 Performing Companies To Watch In Right Now: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 198! 7 and is headquartered in Fos t er City, California.

Advisors' Opinion:
  • [By Ben Levisohn]

    Remember when biotech stocks like Gilead Sciences (GILD) and Celgene (CELG) were getting creamed and everyone was wondering if the biotech boom was finished? Yeah, neither do I.

    We’d better refresh our memories, however. The iShares Nasdaq Biotechnology ETF (IBB) has rallied 20% since dropping 21% from the February 25 through April 11. And large-cap biotech stocks now trade at 16.3 times 2015 earnings versus the S&P 500′s 14.8 times. That, says Nomura’s M. Ian Somaiya and team makes beating earnings forecasts an imperative, who says “lackluster 1Q earnings have increased reliance on solid 2Q results to maintain momentum in the group.”

    Somaiya points to Gilead Sciences, Alexion Pharmaceuticals (ALXN), Celgene and Incyte (INCY) as the biotech companies most likely to beat earnings:

    For Gilead Sciences, we believe Sovaldi sales reach $3bn, almost 2x our $1.6bn and above the Streets $2.6bn estimates, based on strength of prescription data. For Alexion Pharmaceuticals, we believe upside will come from a higher-than-expected rate of patient starts in ROW territories for PNH, a $1-2bn opportunity, and Europe for aHUS. For Celgene, we believe 2Q revenue estimates could be understated due to 1Q seasonality and inventory drawdowns, setting up for a potential beat in Revlimid, Pomalyst and Abraxane. For Incyte, we expect Jakafi sales to bounce back in 2Q, given inventories returned to the low end of the normal range, gross-to-net returns to the 9-10% guidance, and a 4.75% price increase on 1 April. In addition, data presentations at ASCO could have increased off-label usage in pancreatic cancer and PV.

    Shares of Gilead Sciences have gained 1.4% to $89.96 at 1:26 p.m., Alexion Pharmaceuticals has risen 0.6% to $164.22, Incyte has advanced 1% to $51.34 and Celgene has fallen 0.8% to $84.46. The iShares Nasdaq Biotechnology ET! F is up 0! .6% at $258.33.

  • [By John Kimelman]

    In the health-care sector, shares of biotech company Gilead Sciences (GILD) fell 3.45% on the day, following a 14% drop Monday. Gilead has been hit by news tha Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepititas C. AbbVie is a direct rival of Gilead.

  • [By Sean Williams]

    For shareholders of Gilead Sciences (NASDAQ: GILD  ) it's practically been a dream year. Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni.

  • [By John Udovich]

    At the end of this week,congressional scrutiny was weighting down large cap biotech Gilead Sciences, Inc (NASDAQ: GILD) and dragging down much of the biotech sector, but there was still good news surrounding small cap biotech stocks like Endocyte, Inc (NASDAQ: ECYT), Aastrom Biosciences Inc (NASDAQ: ASTM)and TNI BioTech (OTCMKTS: TNIB) plus there were more biotech IPOs which debuted:

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-performing-companies-to-watch-in-right-now-3.html

Wednesday, June 24, 2015

10 Best Income Stocks To Buy Right Now

10 Best Income Stocks To Buy Right Now: Suntory Beverage & Food Ltd (STBFY)

Suntory Beverage & Food Limited is principally engaged in the manufacture and sale of beverages and food. The Company operates in two geographical segments. The Domestic segment is engaged in the manufacture and sale of various soft drinks within Japan, such as coffee drinks, mineral water, green tea drinks, tea drinks, carbonated drinks, fruit juice drinks, functional beverages, milk beverages, and food for specified health use, as well as syrup for general and business usage. The International segment is engaged in the manufacture and sale of carbonated drinks, fruit juice drinks, health food, seasoning, tea-based beverages and others, with operations in Europe, Oceania, Asia and the Americas. As of May 29, 2013, the Company had 80 subsidiaries and 10 associated companies. On October 15, 2013, the Company acquired Lucozade Ribena Suntory Limited. On December 12, 2013, the Company acquired Suntory Beverage & Food Europe Limited. Advisors' Opinion:
  • [By Charles Sizemore]

    Lets start with Suntory Beverage & Food Limited (STBFY),which recently completed its acquisition ofBeam Inc., formerly the purest play on bourbon. Beam was the owner of the eponymous Jim Beam brand, as well as the higher-end Makers Mark and Knob Creek and the lower-end Old Crow.Suntory is Japans leading spirits company, though most Americans will be unfamiliar with its Japanese whisky brands, such as Yamazaki and Hakushu. (Note for booze snobs: Japanese whiskylike Scotch and Canadian whiskyis correctly spelled whisky. American bourbon, Tennessee whiskey and Irish whiskey are correctly spelled whiskey.)

  • [By John Udovich]

    Whiskey has become increasingly cool and popular thanks to the whole cocktail movement, something thats good for big whiskey stocks like Suntory Beverage & Food Limited (OTCMKTS: STBFY), Diageo plc (NYSE: DEO) and Brown-Forman Corporation (NYSE: BF.B) whoalso produce a wide varie! ty ofliquors and beverages. In fact,a recent episode of theDaily Tickercited these stats from a USA Today article:

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/10-best-income-stocks-to-buy-right-now.html

Sunday, June 21, 2015

10 Best Biotech Stocks To Invest In 2015

Discount Dental Materials, Inc. (DDOO)

Today, DDOO remains (0.00%) +0.000 at $1.00 thus far (ref. google finance Delayed: 10:12AM EDT�June 25, 2013).

Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

Take a look at Discount Dental Materials, Inc. (DDOO) 5 day chart:

Top 5 Wireless Telecom Companies To Buy Right Now: Intellicell Biosciences Inc (SVFC)

Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.

The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.

Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on ! its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.

The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.

The Company competes with Cytori Therapeutics, Stem Cell Assurance, Inc., Osiris, Aastrom Biosciences, Aldagen, BioTime, Baxter International, Celgene, Geron, Harvest Technologies, Mesoblast, Regenexx, NeoStem, X-Cell Center, Stem Cells, Athersys, and Tissue Genesis, Life Technologies, Asterand, pacific biosciences of california inc. and AllCells, LLC.

Advisors' Opinion:
  • [By Bryan Murphy]

    To say that shares of IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) has been disappointing since 2011 would be an understatement. SVFC has been an outright disaster since 2011, falling from a peak of $19.00 to a low of, well, just a few pennies as of late last year. In fact, there are those who are understandably wondering how the company is still alive, only producing about a half a million dollars in revenue in 2012, and then dialing that figure back down to nothing for the last few quarters. Yet, there's just something about a company that refuses to go away.... something compelling now.

  • [By Bryan Murphy]

    Well, though I give myself a C for timing, it looks like I'm going to be able to give myself an A for stock-picking. Back on January 27th I deemed IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) was a compelling buy, and though SVFC was stagnant for a month after that, it looks like the stock's finally getting on its horse. If you didn't get it then, you may want to get in now.

10 Best Biotech Stocks To Invest In 2015: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:
  • [By Bryan Murphy]

    Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.

10 Best Biotech Stocks To Invest In 2015: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:
  • [By gurujx]

    Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

    The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

10 Best Biotech Stocks To Invest In 2015: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:
  • [By Keith Speights]

    Last year, Pharmacyclics (NASDAQ: PCYC  ) shares gained a whopping 280%. That was enough to land the biotech a spot on The Motley Fool's list of top health-care stocks in 2012. How is 2013 looking so far? Shares have gained more than 30% year to date but have been anemic since early March.

10 Best Biotech Stocks To Invest In 2015: Incyte Corporation(INCY)

Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Advisors' Opinion:
  • [By John McCamant]

    Incyte's (INCY) crackerjack medicinal chemistry team continues to show that they can create better and differentiated drug candidates from the competition.

    The key near-term driver for INCY is Jakafi growth, and with the increased sales guidance, the company is delivering. The drug's overall profile continues to improve and the recent survival data proves that Jakafi does much more for myelofibrosis patients than just control symptoms.

  • [By John McCamant]

    Incyte Pharmaceuticals (INCY) recently held their quarterly conference call. Importantly, sales for Jakafi��n advanced compound used for the treatment of patients with intermediate or high-risk myelofibrosis (MF)��et or exceeded Wall Street's expectations.

10 Best Biotech Stocks To Invest In 2015: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors' Opinion:
  • [By Maxx Chatsko]

    One company that is about to face the brunt of its patent cliff exposure is Merck (NYSE: MRK  ) , which is set to lose exclusivity for its former megablockbuster Singulair in its last major worldwide markets this year. There are still some interesting molecules in the pipeline and several major approvals pending. However, I don't think Merck stock is worth owning. Here are a few reasons why.

  • [By Value Line]

    The biggest contributors for the year so far were the aforementioned Intel (up 34.1%) and Microsoft (up 23.9%). The Dogs are also contending for a Canine Trifecta, of sorts, counting the three highest performing Industrials amongst their pack; the third being Merck & Co. (MRK), up 18.4%. The drugmaker�� top line has been in decline for three years now, due to patent losses. However, the company has been able to stem the profit erosion through growth in its core franchises.

  • [By Laura Brodbeck]

    Earnings reports expected on Monday include:

    Merck & Company, Inc. (NYSE: MRK) is expected to report third quarter EPS of $0.88 on revenue of $11.19 billion, compared to last year�� EPS of $0.95 on revenue of $11.49 billion. Apple Inc. (NASDAQ: AAPL) is expected to report EPS of $7.88 on revenue of $36.76 billion, compared to last year�� EPS of $8.67 on revenue of $35.97 billion. Biogen Idec Inc. (NASDAQ: BIIB) is expected to report third quarter EPS of $2.10 on revenue of $1.78 billion, compared to last year�� EPS of $1.91 on revenue of $1.39 billion. Herbalife LTD. (NYSE: HLF) is expected to report third quarter EPS of $1.14 on revenue of $1.20 billion, compared to last year�� EPS 0f $1.04 on revenue of $1.02 billion.

    Economics

  • [By Keith Speights]

    Although it has no commercialized drugs to generate revenue, Lexicon has been able to keep going through the years by forming relationships with larger organizations. For example, Lexicon and Merck (NYSE: MRK  ) have worked together for several years to develop biotherapeutic drugs. The partnership with Merck has netted Lexicon $52.5 million in revenue for development.

10 Best Biotech Stocks To Invest In 2015: GW Pharmaceuticals PLC (GWPRF)

GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions. The Company is developing a portfolio of cannabinoid medicines, of which the main product is Sativex, an oromucosal spray for the treatment of Multiple Sclerosis (MS) symptoms, cancer pain and neuropathic pain. The Company operates in three segments: Sativex Commercial, Sativex Research and Development and Pipeline Research and Development. The Company�� wholly owned subsidiaries include GW Pharma Limited, G-Pharm Limited, Cannabinoid Research Institute Limited, Guernsey Pharmaceuticals Limited and GWP Trustee Company Limited. Advisors' Opinion:
  • [By Ben Levisohn]

    But, as the Huffington Post points out, most of the companies that stand to benefit are very small–they make micro caps look big–trade over the counter–good bye liquidity. That includes transaction-processing company MediSwipe (MWIPD), GreenGro Technologies (GRNH) Medbox (MDBX), which makes dispenser for high-risk drugs, and GW Pharmaceuticals (GWPRF).

Thursday, June 18, 2015

Hot Cheapest Companies To Invest In 2015

With shares of Amazon (NASDAQ:AMZN) trading around $311, is AMZN an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.

T = Trends for a Stock’s Movement

Amazon serves its customers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. Amazon offers programs that enable sellers to sell their products on the company�� websites, including the sellers��own branded websites, and fulfill orders through them. Amazon also provides platforms that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and relatively low prices offered.

Amazon unveiled its new Kindle Fire HDX tablets, one with a 7-inch screen and one with a 8.9-inch screen, late on Tuesday night. Amazon�� new Kindle devices are lighter and faster with more memory and longer battery life, according to a report from The New York Times. If users did nothing but read using the 8.9-inch model, the battery life would supposedly last 17 hours. The cheapest of the new Kindle Fire tablets will cost $139. Amazon is releasing the tablets into a competitive market that�� dominated by Apple�� (NASDAQ:AAPL) iPad.

10 Best Safest Stocks To Watch Right Now: Tidewater Inc.(TDW)

Tidewater Inc., through its subsidiaries, provides offshore service vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels. It provides services in support of offshore exploration, field development, and production, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction and seismic support; and various specialized services, such as pipe and cable laying. The company?s vessels include platform supply vessels, and anchor handling towing supply vessels that are used in transporting supplies and equipment from shore bases to deepwater and intermediate water depth offshore drilling rigs, platforms, and other installations; towing-supply and supply vessels used in intermediate and shallow waters; and crewboats and utility vessels that are chartered for transporti ng personnel and supplies from shore bases to offshore drilling rigs, platforms, and other installations. It also operates offshore tugs used for towing floating drilling rigs; assisting in the docking of tankers; towing barges; assisting in pipe laying, cable laying, and construction barges; and commercial towing operations, including towing barges carrying various bulk cargoes and containerized cargo. In addition, the company operates inshore tugs; production, line-handling, and various other special purpose vessels. Further, it operates two shipyards, which construct, modify, and repair vessels. As of March 31, 2011, the company had 378 vessels serving the global offshore energy industry. The company has operations in the United States, Gulf of Mexico, the Persian/Arabian Gulf, and areas offshore Australia, Brazil, Egypt, India, Indonesia, Malaysia, Mexico, Trinidad, Venezuela, and West Africa. Tidewater Inc. was founded in 1956 and is headquartered in New Orleans, Louisi ana.

Advisors' Opinion:
  • [By Traders Reserve]

    For investors who want a piece of this developing trend, Transocean and Seadrill are two of the bigger players in this arena. Other offshore drillers/rig operators are Noble (NE) and Ensco (ESV). Companies that provide services to offshore drillers and benefit from increases in exploration and drilling activity are Gulfmark Offshore (GLF), Hornbeck (HOS), Seacor (CKH) and Tidewater (TDW).

  • [By Seth Jayson]

    When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Tidewater (NYSE: TDW  ) .

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Tidewater (NYSE: TDW  ) , whose recent revenue and earnings are plotted below.

  • [By Garrett Cook]

    Energy shares fell around 0.95 percent in Monday’s trading. Top losers in the sector included Goodrich Petroleum (NYSE: GDP), down 8.39 percent, and Tidewater (NYSE: TDW), off 4.81 percent.

Hot Cheapest Companies To Invest In 2015: China Automotive Systems Inc.(CAAS)

China Automotive Systems, Inc., through its interests in Sino-foreign joint ventures, engages in the manufacture and sale of power steering systems and other component parts for the automotive industry in the People?s Republic of China. It offers a range of steering system parts for passenger automobiles and commercial vehicles. The company provides 4 separate series, 307 models of power steering, including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. China Automotive Systems, Inc. was founded in 2003 and is headquartered in Jing Zhou City, the People?s Republic of China.

Advisors' Opinion:
  • [By Richard Schmidt]

    China Automotive Systems (CAAS), which makes auto systems and components, reported record-high net sales for the third quarter. The report excited investors, who bid the stock up about 30% for the month.

  • [By Richard Schmidt]

    We admittedly bought into China Automotive Systems (CAAS) too soon. The stock is still down from our original recommendation price, but the future looks very bright.

Hot Cheapest Companies To Invest In 2015: Sumitomo Mitsui Financial Group Inc(SMFG)

Sumitomo Mitsui Financial Group, Inc., through its subsidiaries, provides various banking and financial products and services in Japan, the Americas, Europe, the Middle East, Asia, and Oceania. It operates in four segments: Commercial Banking, Securities, Leasing, and Credit Card. The commercial banking segment offers various financial services, including personal bank accounts, investment trusts, pension-type insurance products, life insurance products, and housing loans to individuals; and lending, cash management, settlement, leasing, factoring, management information systems consulting, collection, and investment banking services to mid-sized companies, and small- and medium-sized enterprises. It also provides various financial services, such as loans, deposits, and settlement services, as well as loan syndication, structured finance, and nonrecourse loans to large corporations and listed companies; international banking services comprising project finance, loan syndic ation, securitization, shipping finance, global cash management services, and yen custody services; and provides services related to foreign exchange, securities, and derivatives. The Securities segment offers various financial products, including stocks, bonds, investment trusts, and variable annuity insurance; investment consultation; and administration services to individual and corporate customers. The Leasing segment offers provides leasing services, such as leasing of information and communication equipment, industrial equipment, and construction equipment, as well as aircraft leasing. The Credit Card segment provides various credit cards; and settlement and financing services primarily related to credit card transactions. Sumitomo Mitsui Financial Group, Inc. is headquartered in Tokyo, Japan.

Advisors' Opinion:
  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) - Japanese stocks slipped at the open of trade Tuesday, as the Nikkei Stock Average pulled back from its 2.3% rally in the previous session. The Nikkei Stock Average (JP:NIK) shed 22 points, or 0.1%, to 15,628.07, and the broader Topix was flat at 1,255.14. Financial shares as well as some tech names were under pressure, including Trend Micro Inc. (JP:4704) (TMICY) , shares of which fell 2.8% following their 3% surge on Monday, and Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) as its stock lost 0.8%. In the currency market, the U.S. dollar held above the 楼103 level and the euro moved up toward 楼142.

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) -- Japanese stocks opened higher Tuesday, with shares of exporters supported by further weakness in the yen against the U.S. dollar. The Nikkei Stock Average (JP:NIK) rose 62 points, or 0.4%, to 15,716.60, and the broader Topix gained 0.2%. The dollar on Monday bought more than 楼103 for the first time since May, bolstered by better-than-expected U.S. manufacturing data. Shares of Mazda Motor Corp. (JP:7261) (MZDAF) paced advancers in the auto sector, with their climb of 2.1% adding to Monday's rise of 2.3%. Among tech names, Fujifilm Holdings Corp. (JP:4901) (FUJIF) picked up 1.9%, TDK Corp. (JP:6762) (TTDKF) rose 1.2%. Financial issues, however, were mostly lower, with Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) off 0.2%.

Hot Cheapest Companies To Invest In 2015: Energizer Holdings Inc (ENR)

Energizer Holdings, Inc. (Energizer), incorporated on September 23, 1999, is the manufacturer and marketer of primary batteries, portable lighting and personal care products in the wet shave, skin care, feminine care and infant care categories. The Company manufactures and sells products in five product categories: wet shave, skin care, feminine care, infant care, battery and portable lighting products. On October 23, 2013, it completed the acquisition of the Stayfree pad, Carefree liner and o.b. tampon feminine hygiene brands in the United States, Canada and the Caribbean from McNeil PPC, Inc. and Johnson & Johnson, Inc., members of the Johnson & Johnson Family of Consumer Companies.

Personal Care

The Personal Care division includes wet shave products sold under the Schick, Wilkinson Sword, Edge, Skintimate and Personna brand names, skin care products sold under the Banana Boat, Hawaiian Tropic, Wet Ones and Playtex brand names, and feminine care and infant care products sold under the Playtex and Diaper Genie brand names globally. The Company manufactures and distributes Schick and Wilkinson Sword razor systems, composed of razor handles and refillable blades, and disposable shave products for men and women. The Company markets its wet shave products globally. The Company also manufactures, distributes and sells a complete line of private label and value-priced wet shaving disposable razors, shaving systems and replacement blades. These wet shave products are sold primarily under a retailer's store name or under value brand names such as Personna and GEM.

Household Products

Energizer's Household Products division manufactures and markets product portfolios in household batteries, specialty batteries and lighting products. In household batteries, the Company offers batteries using carbon zinc, alkaline, rechargeable and lithium technologies. The Company distributes its portfolio of household and specialty batteries and portable lighting products th! rough a global distribution network, which also provides a platform for the distribution of its personal care products.

The Company competes with Duracell International, Inc., Panasonic Corporation, Procter & Gamble Company, Bic Group, Kimberly-Clark Corp., Merck & Co., Inc. and Johnson & Johnson.

Advisors' Opinion:
  • [By Johanna Bennett]

    Energizer Holdings (ENR) shed 5.9% to $96.15. The company on Wednesday said its fiscal first-quarter profit slumped to $1.71 a share from $129.8 million in the year-earlier period. Excluding charges, earnings fell to $2.10 a share from $2.20 a share. The company best known for batteries also cut its full-year profit target to $7 a share to $7.25 a share, The Wall Street Journal said.

Hot Cheapest Companies To Invest In 2015: Southern Cross Exploration NL (SXX)

Southern Cross Exploration NL is an Australia-based company engaged in the investment in the Bigrlyi Uranium Joint Venture, on which pre-development investigations and further drilling were carried out; exploration for gold and minerals, reviews of opportunities for participation in and/or acquisition of mineral exploration and mining ventures, and examination of projects in respect of different commodities, share investments, loans and other securities. The Bigrlyi project is located in the Ngalia Basin, northwest of Alice Springs, in the Northern Territory. The Company's interest in the Bigrlyi Uranium Joint Venture is one of its assets, in joint venture with two multi-billion dollar companies, CGNPC - via the Operator, Energy Metals Ltd (EME) - and Paladin Energy Ltd (PDN). Advisors' Opinion:
  • [By idahansen]

    Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.

Hot Cheapest Companies To Invest In 2015: Freeport-McMoran Copper & Gold Inc.(FCX)

Freeport-McMoRan Copper & Gold Inc. engages in the exploration, mining, and production of mineral resources. The company primarily explores for copper, gold, molybdenum, silver, and cobalt. It holds interests in various properties, located in North and South America; the Grasberg minerals district in Indonesia; and the Tenke Fungurume minerals district in the Democratic Republic of Congo. As of December 31, 2010, the company?s consolidated recoverable proven and probable reserves totaled 120.5 billion pounds of copper, 35.5 million ounces of gold, 3.39 billion pounds of molybdenum, 325.0 million ounces of silver, and 0.75 billion pounds of cobalt. The company was founded in 1987 and is headquartered in Phoenix, Arizona.

Advisors' Opinion:
  • [By Lu Wang]

    Mining stocks are bargains after declines in the past two years, said Hodges, who recently bought shares of Freeport-McMoRan (FCX) and U.S. Steel Corp. The selloff since the start of 2011 has erased almost half of the market value from a gauge of seven S&P 500 metal producers, data compiled by Bloomberg show. The price-earnings ratio for Phoenix-based Freeport, the world�� largest publicly traded copper producer, has dropped 24 percent since the beginning of 2010 to 11.5.

  • [By Lee Jackson]

    Freeport-McMoran Copper & Gold Inc. (NYSE: FCX) has been battered as investors have fled mining companies. The company is planning to enter the U.S. oil and gas space, which could truly make it a powerhouse. The company reported strong third-quarter earnings that beat Wall Street expectations convincingly. Fourth-quarter earnings were solid, but sales numbers were slightly lower than expected. Investors are paid a solid 3.5% dividend.�Jefferies has a $45 price target for the stock, and the consensus is posted at $39.85. The stock closed Thursday at $33.68.

  • [By Douglas A. McIntyre]

    In some cases, management decisions may not have had shareholders��best interests at heart. Freeport-McMoRan�� (NYSE: FCX) acquisition of two oil producers in 2012 immediately raised questions of self-dealing and led to a shareholder lawsuit. The lawsuit alleged that, with six board members holding seats on one of the companies involved, Freeport directors were effectively using company funds to bail out their own investment.

Hot Cheapest Companies To Invest In 2015: Constellium NV (CSTM)

Constellium N.V., formerly Constellium Holdco BV, is a Netherlands-based company, which is engaged in the manufacture of aluminum products and solutions. The Company is a supplier of such sectors as: aerospace, automotive and packaging. Constellium Holdco BV offers plates, sheet and coil, precision casting, cockpit carriers for vehicles, vehicle safety components, profiles, as well as tubes and bars, among others. Its main customers include: Airbus, Boeing, Embraer, Audi, BMW, Citroen, Renault, Mercedes Benz, Jaguar and others. The Company is active domestically and abroad, including North America, Europe and Asia. Advisors' Opinion:
  • [By GuruFocus]

    George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

  • [By Jan-e- Alam]

    Constellium (NYSE: CSTM  ) is a downstream aluminum producer engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products. The Netherlands-based company, which offers its products primarily to the aerospace, automotive, and packaging industries, is a world leader in the manufacturing of high-quality aluminum products and solutions.

Wednesday, June 17, 2015

PartnerRe Dipped to Neutral - Analyst Blog

Top 10 Industrial Conglomerate Stocks To Invest In 2016

On Jul 11, we downgraded global life and property-casualty (P&C) insurer and reinsurer – PartnerRe Ltd. (PRE) – to Neutral based on its weak investment portfolio and high competition. While the Presidio acquisition diversifies the company's product profile, it brings in additional costs that will weigh on margins at least for some time.

Why the Downgrade?

Estimates for PartnerRe witnessed modest corrections after the company reported its first-quarter 2013 results on Apr 29, wherein earnings stood at $3.39 per share. Earnings per share outpaced both the Zacks Consensus Estimate and year-ago number of $2.47 and $2.76, respectively. Overall, PartnerRe delivered positive earnings surprises in all of the last 4 quarters with an average beat of 151.1%.

However, total revenue edged down 2.6% year over year to $1.3 billion and was almost in line with the Zacks Consensus Estimate. Growth from premiums written was more than offset by lower investment income.

While total expenses surged 13%, combined ratio improved to 81.7% from 84.7% in the year-ago period. In addition, technical results and underwriting profitability improved, driving growth in bottom line, book value per share and return on equity (ROE).

Following the release of the first-quarter results, the Zacks Consensus Estimate for 2013 inched up 1.8% to $9.25 per share in the last 60 days. Moreover, the Zacks Consensus Estimate for 2014 edged up about 1.0% to $8.11 per share in the last 60 days.

With the Zacks Consensus Estimates for both 2013 and 2014 exhibiting no clear directional pressure in the near term and estimates for both the years posing year-over-year deterioration, PartnerRe now has a Zacks Rank #3 (Hold).

Cause for Concern

The recent acquisition of Presidio not only drove the premiums of PartnerRe but ! also helped the company diversify. Presidio's robust market presence and expert management should further strengthen the company's fundamentals. However, concerns linger over the sustainability of this growth amid the weak P&C market and a history of challenges faced in the integration of ParisRe.

Moreover, intense competition, currency fluctuations, weak credit spreads and low interest rate environment have restricted investment income and yields, thereby limiting the desired upsides. Nevertheless, PartnerRe enjoys above-average liquidity and a low-risk balance sheet, which is reflected in its consistent and efficient capital deployment. In the long run, a stable ratings outlook, improved pricing and market stability can help mitigate the cyclical declines.

Other Insurers That Warrant a Look

While we prefer to avoid PartnerRe until we gain more clarity on the stock's performance, other P&C insurers and reinsurers that are worth a look are AmTrust Financial Services Inc. (AFSI), HCI Group Inc. (HCI) and American Safety Insurance Holdings Inc. (ASI). All these stocks carry a Zacks Rank #1 (Strong Buy).

Sunday, June 14, 2015

A Fool Looks Back

It was a good week to be playing video games. Activision Blizzard  (NASDAQ: ATVI  ) moved sharply higher on Friday after striking a deal to buy most of the shares held by majority stakeholder Vivendi. Earlier in the week, Electronic Arts  (NASDAQ: EA  ) gained ground after posting a much narrower quarterly deficit than analysts were expecting.

It's certainly way too early to think they either company has won this game. Why is Vivendi cashing out now? Meanwhile, a smaller loss at EA is still a loss.

The trends also continue to work against the video-game companies as mainstream gamers seem to be just fine playing free ad-based apps, leaving a thinner crowd of diehard gamers willing to pay up for the more intricate console-based experiences.

The news was certainly good this week, but the real test will come this holiday season, when the new consoles hit the market.

Briefly in the news
And now let's take a quick look at some of the other stories that shaped our week.

Amazon.com  (NASDAQ: AMZN  ) surprised investors with a quarterly loss. Analysts were calling for a small profit. But should the market really be surprised? Amazon has come up short on the bottom line in three of the past four quarters. Clearly, CEO Jeff Bezos is willing to sacrifice near-term margins for the sake of growing the e-tailer's business for the long haul. A company that did break from its recent trend of coming up short was Baidu  (NASDAQ: BIDU  ) . China's leading search engine came through with better-than-expected results. It had missed on the bottom line in its two previous quarters. Baidu's guidance calls for accelerating revenue growth, silencing doubters who have argued that it was all downhill for the former dot-com darling. 8x8  (NASDAQ: EGHT  ) hit a fresh 52-week high this week after posting well-received quarterly results. The provider of telecommunications services for companies now has more than 33,000 business customers. If your name is 8x8, it's nice to know that you can multiply.

Best Valued Stocks To Buy For 2016

Dividend stocks will make you rich. It's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of the only nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Saturday, June 13, 2015

Top Food Stocks To Own For 2016

Top Food Stocks To Own For 2016: Sao Martinho SA (SMTO3)

Sao Martinho SA is a Brazil-based holding company primarily engaged in the sale and production of sugar and ethanol. It is engaged in the cultivation of sugar cane and production and sale of sugar, ethanol and other sugar cane products. The Company is also involved in the cogeneration of electricity and cattle breeding, as well as the provision of agricultural products. The Company produces hydrous ethanol, anhydrous ethanol, industrial ethanol, ribonucleic acid, fuel oil, yeast, sugar and sugarcane biogases, used to generate steam and electricity. Through its subsidiary Omtek, the Company produces ribonucleic acid (RNA) sodium salt, which is used in the pharmaceutical and food industries as a raw material and flavor enhancer. The Company operates through a numerous subsidiaries, including Vale do Mogi Empreendimentos Imobiliarios SA, SMA Industria Quimica SA, Usina Santa Luiza SA, Sao Martinho Energia SA and Santa Cruz SA, among others. Advisors' Opinion:
  • [By Ney Hayashi]

    Sugar and ethanol producer Sao Martinho SA (SMTO3) fell 1.8 percent to 25.53 reais after posting a quarterly profit that missed analysts estimates.

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-food-stocks-to-own-for-2016.html

Friday, June 12, 2015

Top 10 Mid Cap Stocks To Buy Right Now

Top 10 Mid Cap Stocks To Buy Right Now: MER Telemanagement Solutions Ltd.(MTSL)

Mer Telemanagement Solutions Ltd., together with its subsidiaries, designs, develops, markets, and supports a line of telecommunication expense management (TEM), and customer care and billing solutions for business organizations and other enterprises worldwide. Its TEM solutions assist enterprises and organizations in the allocation of costs, budget control, fraud detection, processing of payments, and spending forecasting. The company also offers converged billing solutions, including applications for charging and invoicing customers, interconnect billing, and partner revenue management through pre-pay and post-pay schemes for wireless providers, voice over Internet protocol, Internet protocol television, and content service providers. Its products provide telecommunication and information technology managers with tools to reduce communication costs, recover charges payable by third parties, and to detect and prevent abuse and misuse of telephone networks comprising fault telecommunication usage. The company markets its products through its direct sales force, distributors, and business telephone switching systems manufacturers and vendors. Mer Telemanagement Solutions Ltd. was founded in 1995 and is headquartered in Raanana, Israel.

Advisors' Opinion:
  • [By Bryan Murphy]

    If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.

  • [By Monica Gerson]

    MER Telemanagement Solutions (NASDAQ: MTSL) dropped 14.62% to $2.09 after the c! ompany terminated MVNE solution provider agreement with SBC Communications.

  • [By James E. Brumley]

    Trading can be a quirky game sometimes. Most of the time, news - or at least loudly voiced opinions - tend to result from or be the cause of a fast-moving stock. Every now and then though, as in the case with MER Telemanagement Solutions Ltd. (NASDAQ:MTSL), a stock can build up steam with little to no news linked to that move. That doesn't make that stock a poor pick, however. Indeed, MTSL looks like it's turning into a homerun, and that alone is worth a look.... and maybe even worth a shot.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-mid-cap-stocks-to-buy-right-now-3.html

Wednesday, June 10, 2015

This Sector Is About to See a Huge Jump in Profits

Top 10 Beverage Stocks To Watch For 2016

The crisis is OVER for big banks...   During the 2008-2009 credit crisis, financials were one of the worst-hit sectors. Without cash injections from our government, several big companies in this sector may have fallen into bankruptcy. That includes heavyweights like Citigroup and Bank of America.   But things are looking much better these days. And bank stocks are setting up to be huge winners over the next 12 months.   In the first few years following the crisis, banks faced huge headwinds. The housing market was still depressed. In short, there were tons of foreclosures (bad assets) on the balance sheet of banks. These homes couldn't be sold at market prices.   Plus, heavy regulation was on the way. Most new rules proposed by our government were designed to shrink banks – which in turn would lower profits.   Under these conditions, it did not make much sense to own banks.   However, many of these conditions have now reversed. And many banking stocks – despite their quick move higher over the past few months – stand to benefit greatly both in the short and long term.   Let me explain...   Over the past two months, interest rates have been on a tear. The 10-year Treasury bond yield is up 49%. And mortgage rates have jumped from 3.4% to 4% (an 18% increase) in the same time frame. These are both 15-month highs. And for interest rates... those are major moves in such a short period.     Rising interest rates are widely viewed as a negative for stocks. Borrowing costs for consumers and businesses are moving higher. Plus, higher interest rates could persuade investors to move their money out of stocks and into interest-paying alternatives.   But higher interest rates are great for bank stocks. That's because the spread between the cost to borrow money and the actual rates banks can charge their customers widens.   You see, banks have plenty of cheap money at their disposal. (The average interest rate on a savings account, for example, is about 0.44% right now.) But with interest rates on long-term debt rising, banks can lend that money back out at much higher rates – in a mortgage at 4%, for example.   The higher those rates go, the wider the spread gets... and the bigger the banks' profits.   Last week, JPMorgan CEO Jamie Dimon explained that if interest rates climbed 300 basis points (3%), his bank would make an extra $5 billion in profits.   And rising interest rates are not the only reason to own bank stocks...   Today, home prices are rising at their fastest pace in seven years. Keep in mind, many large banks wrote down billions of dollars in mortgages in the past few years. Now that the housing market is rebounding, some of these foreclosed homes can now be sold. If the housing market continues to rebound – which most experts predict – this will result in huge profits for banks going forward.   Also, banks have done a great job adapting to new regulations. Sure, new capital requirements have resulted in lower profits. But almost every management team in the banking industry has updated investors about their progress on these new rules in each passing quarter. Now that most have been implemented, this risk seems largely priced in to bank stocks here.   To play this banking trend, you can buy individual names like Bank of America (huge leverage to housing) or JPMorgan (major beneficiary of rising interest rates). Based on the catalysts mentioned above, I'm confident these two names will easily outperform the market in the short and long term.   Another good way to play this trend is to buy the Financial Select Sector SPDR Fund (XLF). Its top holdings include some of the biggest banks in North America. The yield on XLF is 1.6%, lower than the average S&P 500 company. But I expect earnings to grow at least three times faster over the next 12 months. That makes XLF, trading at 11 times earnings, dirt-cheap.   I suggest adding some financial exposure to your portfolio right away.   Good investing,   Frank Curzio



Tuesday, June 9, 2015

For Netflix, Binge-Viewing Isn't the Answer

I'm an Arrested Development fan. I really did love those first three seasons and have watched them more than once. So it would make sense that I should be excited for the new season just out on Netflix (NASDAQ: NFLX  ) . But honestly, I've been more skeptical than anything else. 

To be a skeptic
I'll chalk my skepticism up to any number of reasons. Seven years have passed since the series wrapped up, which is a long time. Part of the genius of the show from the beginning for me was the writing, and I just have a hard time coming to grips with the new season being anything more than simply an effort to get a few more episodes out. For me the hurdle was very high to begin with; sometimes it's OK to just pull a Paul McCartney and let it be. 

I'm not one to pay much attention to critics, but when I read in The New York Times, "If you truly loved (the first three seasons of 'Arrested Development'), it's hard to imagine being anything but disappointed with this new rendition," I realized that I was thinking that before it ever even came out. Ay caramba indeed.

I'm sure I'll end up checking it out at some point or another, but it'll be awhile. I'm not even a Netflix subscriber. Netflix has nothing I want or need, so why subscribe to it? No, I haven't seen House of Cards. I've been busy watching Time Warner's HBO. But this all leads me to my greater point: Netflix may want to seriously rethink their binge-viewing strategy, as it could most certainly come back to bite them.

Trouble in binge-ville?
Here's the thing: Binge-viewing does work... for some shows. Older shows that have already been around the block are perfect for binge-viewing if that's your thing. But if Netflix's strategy is to develop more original content in order to differentiate themselves (and I agree with this move... they need to do something because they are becoming less and less special every day given the competition that's growing out there), they are going to need to think ab! out stretching out the lives of these things. 

House of Cards is a good example. I'm sure the show is fine. It certainly received great reviews. But that's over now. Nobody's talking about it anymore. Anywhere. Viewers are going to have to wait until, like, next March to see new episodes. That takes the entire life out of the show as far as I can see it. It was like a season in a week. Doneski.

Let's look at other end of the spectrum. Game of Thrones (or we can go with Breaking Bad, Sons of Anarchy, American Horror Story, Boardwalk Empire, Downton Abbey -- you get my point). These shows are living long and healthy lives as linear shows on a weekly schedule. Of course, you can binge-view older seasons. You can also just wait for the new stuff to eventually come out on Netflix, Amazon's Prime service or Apple's iTunes. And there's no question that some shows have benefited from being on these platforms as they've become accessible to many who might not have seen them otherwise.

But Game of Thrones et al are shows that actually benefit from the linear schedule. It gives them (and hence their developers) longer lives; it keeps people interested and tuned in longer. People talk about these shows every week in my office. House of Cards, not so much. Given the following that Downton Abbey continues to grow, it certainly makes Amazon's move to gain exclusive rights to that show look shrewd indeed.

This is the point, right here
If I can watch all of Arrested Development in one night, then bam! -- it's over. One freaking night and an entire season of "original" (and not cheap) content is done. So what this potentially leads Netflix to is having to produce more stuff. A lot more stuff. And it costs a lot of money to produce a lot of stuff (at least stuff worth watching). This works out great for subscribers because, hey, they're getting more stuff and paying a measly $7.99 a month. But investors may be getting the short end of the stick here. The company will issue more debt to produce more stuff, and when they release it all at once, then they'll need to make even more stuff. Again, great if you're a subscriber paying $7.99 per month. But all things considered, I've got zero interest in investing in Netflix, particularly at today's prices. And by the way, I am calling it now: They will be issuing more debt within the year.

Two things to take away
I wholeheartedly admit that I could be totally wrong about all of this. CEO Reed Hastings knows a heck of a lot more about this business than I do. Netflix is a good business and Hastings is a smart guy with some great ideas. But Netflix needs to do two things in my estimation (and that may not be all). It needs to start seriously thinking about how it can raise prices and it needs to seriously rethink releasing all of its original content at once. It's just a nasty pace to have to keep up with and I wouldn't want to count on being able to do it indefinitely. Again, great for subscribers; but scary as hell for investors.

The Motley Fool has released a premium report on Netflix. Inside, you'll learn about the key opportunities and risks facing the company, as well as reasons to buy or sell the stock. The report includes a full year of updates to cover critical new developments; click here and claim your copy today.

Monday, June 8, 2015

Best Prefered Stocks To Buy For 2016

Best Prefered Stocks To Buy For 2016: Nordion Inc. (NDZ)

Nordion Inc., a health science company, provides various products and services for the prevention, diagnosis, and treatment of diseases worldwide. The company operates in two segments, Sterilization Technologies and Medical Isotopes. The Sterilization Technologies segment offers Cobalt-60, a radioactive metal that emits radiation and sterilizes items by destroying contaminating micro-organisms; and dosimetry and professional services, as well as designs, constructs, and maintains commercial gamma sterilization systems. The Medical Isotopes segment provides various products that are used in the diagnosis and treatment of diseases, including cardiac and neurological conditions, and various types of cancer. It offers Molybdenum-99, which decays into Technetium-99, a diagnostic that is used in nuclear medical procedures; Xenon-133 used in lung scans; Iodine-131 to treat hyperthyroidism, thyroid cancer, and non-Hodgkin's lymphoma; Iodine-125 to treat prostate cancer; and Yttri um-90 to treat liver cancer and non-Hodgkin's lymphoma. This segment also provides cyclotron isotopes, such as Iodine-123 to diagnose thyroid disease; Thallium-201 to diagnose and assess risk of coronary artery heart disease; Palladium-103 for treating prostate cancer; Strontium-82 for cardiac imaging; and Indium-111 and Gallium-67 to diagnose cancer, as well as offers radiopharmaceutical and contract manufacturing services. Nordion Inc. serves radiopharmaceutical and pharmaceutical manufacturers, biotechnology companies, manufacturers of medical supplies and devices, contract sterilizers, hospitals, and academic and government institutions, as well as to food and consumer goods industries. The company was formerly known as MDS Inc. and changed its name to Nordion Inc. in November 2010. Nordion Inc. was founded in 1946 and is headquartered in Ottawa, Canada.

Advisors' O! pinion:
  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Nordion (NYSE: NDZ) and Insmed (NASDAQ: INSM).

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Nordion (NYSE: NDZ) and Pacira Pharmaceuticals (NASDAQ: PCRX). Utilities sector rose by just 0.19 percent in the US market today.

  • [By Louis Navellier]

    The trick to profiting in international markets is the same as it is here at home: Use Portfolio Grader to focus on the international stocks with the very best fundamentals that are attracting buying pressure from institutions.

    Great International Stocks: Nordion (NDZ)

    Nordion (NDZ) is a Canadian health sciences company whose products are used to diagnose, prevent and treat diseases around the world. The company's primary products are isotopes used in nuclear medicine such as Molybdenum-99, which decays into Technetium-99, utilized in nuclear medical procedures.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/best-prefered-stocks-to-buy-for-2016.html

Sunday, June 7, 2015

Top 10 Net Payout Yield Companies For 2016

Top 10 Net Payout Yield Companies For 2016: Reliv' International Inc.(RELV)

Reliv? International, Inc. develops, manufactures, and markets nutritional supplements. Its basic nutrition supplements include Reliv Classic and Reliv NOW, a blend of vitamins, minerals, proteins, and herbs; NOW for Kids, which provides a balanced nutritional supplement for a child?s diet; and Reliv Delight, a powdered nutritional supplement marketed as a milk replacement. The company?s specific wellness supplements comprise ReversAge, a nutritional supplement to slow down the effects of the aging process; SoySentials for use by women; CardioSentials that promotes heart health; Arthaffect, which supports healthy joint function; FibRestore that contains fiber, vitamins, minerals, and herbs; GlucAffect, which assists in healthy blood sugar management and support weight loss; and 24K, a ready-to-drink nutritional supplement that enhances the body?s natural vitality. Its weight management supplements consist of Slimplicity meal replacement and accelerator capsules; Reliv Ultr im-Plus, a meal replacement product; and Cellebrate, a weight loss aid. The company?s sports nutrition supplements include Innergize!, a sports supplement containing vitamins and minerals for performance enhancement; and ProVantage to enhance muscle recovery, muscle mass, and function, as well as to reduce fatigue and burn excess body fat for extra energy. It also offers Relivables product line, which comprises skin care products, marketed as the ?r? skin care collection, as well as food products, such as Relivables All-Natural Sweetener, Relivables Fortified Soy Milk, Relivables Soy Nuts, and Relivables Healthy Snack Bars. Reliv? International markets and sells its products through a network of independent distributors in the United States, Australia, Austria, Brunei, Canada, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Singapore, and the United Kingdom. The company was founded in 1984 and is headqu! artered in Chesterf ield, M issouri.

Advisors' Opinion:
  • [By John Udovich]

    Last Friday, small cap dieting stock Weight Watchers International, Inc (NYSE: WTW) lost weight for investors when shares tumbled27.73% to $22.10, meaning its probabaly a good idea to take a closer lookat the stock along withother small cap weight loss or dieting stocks like NutriSystem Inc (NASDAQ: NTRI), Medifast Inc (NYSE: MED) and Reliv International, Inc (NASDAQ: RELV). Why did Weight Watchers International loose weight last Friday? The company reported its fourth straight quarterly sales decline as fewer people attended meetings and bought its products and also projected earnings that trailed analysts' estimates with the blame being placed on new mobile applications and bracelets that track calories thushurting traditional diet companies.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-net-payout-yield-companies-for-2016.html

Thursday, June 4, 2015

Learning From the Beer Pioneers

When Boston Beer (NYSE: SAM  ) founder Jim Koch decided to start up a brewery in 1984, his inspiration came from his family -- in a reverse sort of way. As the well-told tale goes, Jim's dad -- a fifth-generation brewer -- tried to steer him away from a business he saw as too tough because of the ongoing wave of consolidation.

But today Jim's company is the largest craft brewer in the nation, with almost 1% of total beer sales. Many at the recent Craft Brewers Conference count Boston Beer among their most-admired companies. Our Rex Moore took on the tough assignment of covering the conference, and asked about other companies these brewers learned from. Today, Port City Brewing founder Bill Butcher talks about fellow craft beer maker Sierra Nevada.

A Boston buy?
Boston Beer's Samuel Adams brand helped to redefine beer and kick off the craft beer revolution in the United States. Success breeds competition, though, and while just a few years ago Boston Beer had claim over most of the craft beer shelf, today the field is crowded. Can Boston Beer rise above the rest, or will it be squeezed between small local breweries on one side and global beer giants on the other? To help you decide, we've compiled a premium research report filled with everything you need to know about Boston Beer's risks and opportunities. Just click here now to find out whether Boston Beer is a buy today.

Wednesday, June 3, 2015

Top Gas Companies To Own In Right Now

In any industry, investors weigh the relative merits of the best growth stocks versus the best value stocks.

And in the race to tap into the burgeoning natural gas vehicle market, the growth stock has typically ruled the day. Westport Innovations (Nasdaq: WPRT) has become quite well known among energy industry investors while rival Fuel Systems Solutions (Nasdaq: FSYS), a struggling value stock, disappeared off radars.

Back in April, I suggested that investors should give Fuel Systems Solutions a fresh look, as a solid near-term catalyst was in place: GM (NYSE: GM) was gearing up to launch new pickup trucks with Fuel Systems' compressed natural gas (CNG) engines. And shares are up more than 30% since then. I still think Fuel Systems is a solid investment opportunity, but I also think it's time to give Westport -- the former industry high-flier -- a fresh look.

Best Managed Healthcare Companies To Watch For 2016: Neste Oil Corp (NES1V)

Neste Oil Corp is a Finland-based company engaged in the refining and marketing of petroleum and petroleum products. The Company has two business areas and four reporting segments. The business areas are: Oil Products & Renewables and Oil Retail. The reporting segments are: Oil Products, Renewable Fuels, Oil Retail and Others. The Oil Products & Renewables area produces and sells petroleum products such as gasoline, diesel fuel, aviation and bunker fuel, heating oil, heavy fuel oil, base oil, gasoline components, specialty fuels, fuels, liquefied petroleum gas (LPG) and bitumen as well as renewable diesel and aviation fuel under the brand name NExBTL. The Oil Retail area operates a network of 1,136 stations in Finland, the Russian Federations, the Baltic states and Poland, selling own products as well as lubricants and chemicals. The Company owns fuel refineries and production plants in Finland, Singapore and the Netherlands. Advisors' Opinion:
  • [By Sarah Jones]

    Neste Oil Oyj (NES1V) gained 4.8 percent to 12.04 euros. CA Cheuvreux SA upgraded Finland�� only refiner to outperform, the equivalent of a buy recommendation, from underperform, saying it expects it to report resilient first-quarter results this month.

  • [By Corinne Gretler]

    Neste Oil Oyj (NES1V) declined 9.1 percent to 14.25 euros after Citigroups Inc. cut Finland�� only oil refiner to sell from neutral, citing a deterioration in key profitability drivers for both renewables and refining divisions.

Top Gas Companies To Own In Right Now: Endeavour International Corp (END)

Endeavour International Corporation (Endeavour), incorporated on January 13, 2000, is an independent oil and gas company engaged in the exploration, development and acquisition of energy reserves in the United States and United Kingdom. The Company has three producing fields in the United Kingdom, including Alba, Bacchus and Bittern, as well as a number of development projects including Rochelle and Columbus. In the United States, the Company has production in the Haynesville and Marcellus, as well as two oil frontier plays in Colorado and Montana. As of December 31, 2012, Endeavour had proved reserves of 71,591 million cubic feet (MMcf) of natural gas and 13,739 thousands of barrels (Mbbls) of crude oil for a combined 25.7 million barrels of oil equivalent (MBOE).

The North Sea is a resource area where it has a development project, producing properties and additional exploration licenses. During 2012, Alba production volumes were impacted by water handling issues. As of December 31, 2012, it held a 30% working interest in its Bacchus field asset, which is operated by Apache Corporation, who owns a 50% working interest. In April and July 2012, it achieved production from the first and second development wells, respectively, on the Bacchus field. The Company�� working interest in the Rochelle area is 44% and it is the operator of the field, which is comprised of Blocks 15/26b, 15/26c and 15/27. Its United States activity has targeted reserve and production growth in shale gas plays, including the Louisiana Haynesville and Pennsylvania Marcellus areas.

The Company is also targeting emerging oil-prone and liquids-rich plays, including the Montana Heath oil play and its new interests in the Colorado Niobrara area. The Company operates and controls the Marcellus assets while retaining a 50% position in its remaining producing Haynesville acreage. The Company has 19 Haynesville Units which held by production with an estimated over 80 remaining gross locations to be developed, dep! ending on development well spacing. The Company has interests in approximately 88,900 net acres in the emerging Heath Shale oil play in Montana, primarily in Rosebud and Garfield Counties.

Advisors' Opinion:
  • [By Jon C. Ogg]

    Endeavour International Corp. (NYSE: END) was downgraded to Hold from Buy at Canaccord Genuity.

    Endo Health Solutions Inc. (NASDAQ: ENDP) was downgraded to Sell from an already cautious Neutral rating at Janney.

Top Gas Companies To Own In Right Now: NK Lukoil OAO (LKOH)

NK Lukoil OAO (Neftyanaya Kompaniya LUKOIL OAO or NK LUKOIL OJSC) is a Russia-based integrated oil and gas company. The Company is engaged in the business of oil exploration, production, refining, marketing and distribution. It is an owner of refineries, gas processing, petrochemical plants and gas stations network located in Russia, Eastern and Western Europe, as well as Africa. The Company�� petroleum products are sold in the Russian Federation, the Commonwealth of Independent States (CIS) countries, Eastern and Western Europe, Asia and the United States. NK Lukoil OAO operates through numerous subsidiaries and affiliated companies. In April 2013, the Company acquired a 100% of Samara-Nafta ZAO and completed acquisition of CJSC Kama-Oil. In June 2013, it sold a 99.57% stake in Lukoil Odes'kyi NPZ PAT. The Company�� major shareholder is NKO ZAO NRD with a stake of 91.60%. In December 2013, it consolidated a 100% stake in ISAB Srl. Advisors' Opinion:
  • [By Maria Levitov]

    Russia�� Micex Index extended a five-day drop to 3.4 percent, led by OAO Lukoil (LKOH) and OAO Gazprom. Ukraine�� dollar-denominated bonds gained, sending yields to the lowest this week, as President Viktor Yanukovych announced possible investments from China. The PX Index slid to a seven-week low in Prague as Vienna Insurance Group AG plunged 4.2 percent.

Top Gas Companies To Own In Right Now: Vermilion Energy Inc (VET)

Vermilion Energy Inc. (Vermilion), is engaged in the business of oil and natural gas exploitation, development, acquisition and production in Australia, Canada, France, Ireland and the Netherlands. As of December 31, 2011, Vermilion holds an average working interest of 68.5% in 395,616 (271,067 net) acres of developed land, 582 (396 net) producing natural gas wells and 319 (198 net) producing oil wells in Canada. Vermilion holds an 83.6% working interest in 193,017 acres of developed land in the Aquitaine and Paris Basins. Vermilion's Netherlands assets consist of eight onshore concessions and one offshore concession located in the northern part of the country. In October 2013, Vermilion Energy Inc, through its wholly owned subsidiary acquired Northern Petroleum Nederland B.V. Advisors' Opinion:
  • [By Marc Bastow]

    Oil exploration and production company Vermillion Energy (VET) raised its monthly dividend 7.5% to 21.50 cents (Canadian) per share, and is expected to be payable on February 17.
    VTE Dividend Yield: 1.52%

Top Gas Companies To Own In Right Now: FX Energy Inc (FXEN)

FX Energy, Inc. is an independent oil and gas exploration and production company with production, appraisal, and exploration activities in Poland. The Company operates within two segments of the oil and gas industry: the exploration and production (E&P) segment in Poland and the United States, and the oilfield services segment in the United States. The Company also has oil production, oilfield service activities, and a shale acreage position in the United States. During the year ended December 31, 2011, its oil and gas production was 4.4 billion cubic feet of natural gas (12.0 million cubic feet equivalent per day). The Company concentrates its exploration operations in Poland primarily on the Rotliegend sandstones of the Permian Basin. The Company has identified a core area consisting of approximately 852,000 gross acres surrounding PGNiG�� producing Radlin field.

Activities and Presence in Poland

The Company conducts its activities in Poland in project areas, including Fences, Blocks 287, 246, and 229 near the Fences concession, Warsaw South, Kutno, Northwest, and Edge. In the Fences during 2011, it completed the Lisewo-1 well as a commercial well and drilled the Plawce-2 well in a tight sand area. In its other concessions it drilled the Machnatka-2 well, a noncommercial Zechstein/Carboniferous test, in the Warsaw South concession, and started drilling the Kutno-2 well, a deep Rotliegend test, in the Kutno concession. The Fences concession area encompasses 852,000 gross acres (3,450 square kilometers) in western Poland�� Permian Basin. The Fences concession area encompasses 852,000 gross acres (3,450 square kilometers) in western Poland�� Permian Basin. The Company has drilled 11 conventional wells targeting Rotliegend structures through the date of this filing. Eight of these wells are commercial. The Company is produce from four of these eight wells.

The Block 287 concession area is 12,000 acres (50 square kilometers) located approximately 25 miles so! uth of the Fences concession area. The Company owns 100% of the exploration rights. As of December 31, 2011, it has reentered only the Grabowka-12 well. During 2011, it produced at an average daily rate of approximately 0.2 million cubic feet of natural gas per day. The Company has a 100% interest in a concession south of its Fences project area covering approximately 241,000 acres (975 square kilometers). The Company hold a 51% interest in a total of 874,000 acres (3,538 square kilometers.) in east-central Poland. During 2011, it entered into a farmout agreement with PGNiG under which it earned a 49% interest in the entire Warsaw South concession in return for paying certain seismic and drilling costs. It subsequently drilled the Machnatka-2 well to test Zechstein and Carboniferous potential in the western part of the concession area.

The Company holds a 100% interest in 706,000 acres (2,856 square kilometers). The area encompasses a Rotliegend structure (Kutno) with projected four-way dip closure. It started drilling the Kutno-2 well during 2011. It hold concessions on 828,000 acres (3,351 square kilometers) in west-central Poland, in Poland�� Permian Basin directly north of PGNiG�� BMB and MLG oil and gas fields. The Company has a 100% interest in four concessions in north-central Poland covering approximately 881,000 acres (3,567 square kilometers). As of December 31, 2011, it held oil and gas exploration rights in Poland in separately designated project areas encompassing approximately 4.6 million gross acres. The Company is the operator in all areas, except its 852,000 gross-acre core Fences project area, in which it hold a 49% interest in approximately 807,000 acres and a 24.5% interest in the remaining 45,000 acres.

U.S. Activities and Presence

The operations consist of shallow, oil-producing wells in the Southwest Cut Bank Sand Unit (SWCBSU), of Montana. Its oil wells produce approximately 155 barrels of oil per day, net to its interest. From its fie! ld office! in Montana, the Company also provides oilfield services. The Company produces oil from approximately 10,732 gross (10,418 net) acres in Montana and 400 gross (128 net) acres in Nevada. In 2011, the Company entered into a joint venture with two other companies, American Eagle Energy, Inc., and Big Sky Operating LLC, in which it pooled our approximately 10,000 net acres in our SWCBSU with their approximately 65,000 net acres, the Americana leases, along with a farmout agreement that provides the group with an ability to earn an interest in an additional 7,000 acres covered by the Somont leases. During 2011, it drilled three vertical wells on joint venture acreage to obtain log and core data. The Company also drilled a 3,600-foot lateral from one of these three wells, the Anderson 14-29, and carried out a multistage fracture. The Company is testing oil potential in the Anderson 14-29 well. The Company has a one-third working interest in all formations below the Cut Bank in its SWCBSU.

Advisors' Opinion:
  • [By Roberto Pedone]

    An under-$10 energy player that's trending very close to triggering a major breakout trade is FX Energy (FXEN), which is an independent oil and gas exploration and production company with principal production, reserves and exploration in Poland and oil production, oilfield service and exploration activities in the U.S. This stock has been under selling pressure so far in 2013, with shares off by 12.6%.

    If you take a look at the chart for FX Energy, you'll notice that this stock recently formed a double bottom chart pattern at $2.82 to $2.93 a share. Following that bottom, shares of FXEN are now starting to uptrend and push back above its 50-day moving average of $3.41 a share. That move is quickly pushing shares of FXEN within range of triggering a major breakout trade above a key downtrend line that started back in late May.

    Traders should now look for long-biased trades in FXEN if it manages to break out above its 200-day moving average at $3.75 a share and then once it takes out more near-term overhead resistance at $3.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 478,408 shares. If that breakout triggers soon, then FXEN will set up to re-test or possibly take out its next major overhead resistance levels at $4.50 to $4.76 a share. Any high-volume move above those levels will then put its May high at $6.18 into range for shares of FXEN.

    Traders can look to buy FXEN off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.11 to $2.93 a share. One can also buy FXEN off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  • [By James E. Brumley]

    If it seems like you've heard the market buzzing about FX Energy, Inc. (NASDAQ:FXEN) quite a bit of late, you're not crazy - it's been in the spotlight a little more than usual over the past few weeks. And for good reason. FXEN shares are about to explode higher. All they need is the right nudge. More on that in a second.

Top Gas Companies To Own In Right Now: Halcon Resources Corp (HK)

Halcon Resources Corporation (Halcon Resources), incorporated on February 5, 2004, is an independent energy company focused on the acquisition, production, exploration and development of onshore liquids-rich oil and natural gas assets in the United States. The Company has oil and natural gas reserves located primarily in Texas, North Dakota, Louisiana, Oklahoma and Montana. On August 1, 2012, the Company acquired GeoResources by merger. On December 6, 2012, the Company completed the acquisition of entities owning approximately 81,000 net acres prospective for the Bakken / Three Forks formations primarily located in Williams, Mountrail, McKenzie and Dunn Counties, North Dakota (the Williston Basin Assets), from Petro-Hunt, L.L.C. and Pillar Energy, LLC (the Petro-Hunt parties). As of December 31, 2012, the Company has working interests in approximately 128,000 net acres prospective for the Bakken / Three Forks formations in North Dakota and Montana.

The Company�� Woodbine / Eagle Ford acreage is prospective for the Woodbine, Eagle Ford and other formations, with targeted depths ranging anywhere from 7,000 feet to 10,400 feet. As of December 31, 2012, The Company has approximately 198,000 net acres leased or under contract primarily in Leon, Madison, Grimes, Brazos, and Polk Counties, Texas. The Company is the operator and has a 100% working interest in more than 12,000 net acres in Wichita and Wilbarger Counties, Texas that it is actively water flooding in shallow Cisco aged Pennsylvania sandstone and limestone reservoirs. As of December 31, 2012, the Company produced 484 million barrels of oil equivalent from approximately 700 active producing wells and approximately 230 active water injection wells.

The Company�� position in the La Copita Field covers 3,720 gross acres and 2,829 net acres in Starr County, Texas. As of December 31, 2012, the Company�� average net daily production was 623 barrels of oil equivalent per day. The Company operates 100% of this production a! nd its working interest ranges from 75% to 100%. The Company has various other oil and natural gas properties with varying working interests located across the United States, including the Austin Chalk Trend and Eagle Ford Shale in Texas, the Fitts-Allen Fields in Central Oklahoma, and various other areas across South Louisiana, Montana, North Dakota, New Mexico, and West Virginia.

Advisors' Opinion:
  • [By Joel South and Taylor Muckerman]

    In the video below, Motley Fool analysts Joel South and Taylor Muckerman discuss a recent operational update from Halcon Resources (NYSE: HK  ) , showing even stronger growth than the company had projected. Joel highlights a few recent wells for the company in the Fort Berthold region in North Dakota that have been very strong performers, and discusses the company's large production increases both in that region and in the Eagle Ford region in Texas. He also tells us about the operational efficiencies that have led the company to bring home these higher yields.

  • [By Tyler Crowe]

    Who's next?
    Kodiak Oil & Gas isn't the only one that has employed this growth strategy in the Bakken, and several other companies that are either Bakken-centric or have smaller assets in the region will also struggle with these new regulations. The companies that immediately come to mind are Oasis Petroleum and Triangle Petroleum because they are pure plays, but two other companies that could be at risk here are Halcon Resources (NYSE: HK  ) and Magnum Hunter Resources (NYSE: MHR  ) . While Magnum Hunter and Halcon do have assets elsewhere, they have both been using the Bakken as a production base to generate revenue while they explore less established shale formations. Based on the cash flow at these companies, they can ill afford to see production limited in the Bakken.

  • [By Value Digger]

    A) Halcon Resources (HK) is a US-based oil-weighted producer. I was bearish on Halcon at $8 when I shorted it, for the reasons mentioned here. I also noted then that the traders and the speculators pushed Halcon to an outrageous overvaluation at $8.

  • [By David Sterman]

     

    2. Halcon Resources (NYSE: HK) Insiders bought more than $2 million of this energy exploration firm in early August as part of a secondary share offering priced at $5.10 a share. In the past 10 days, as shares have slipped below the $5 mark, insiders have continued to accumulate shares.

    Halcon has a legion of fans in the financial blogosphere, and this recent post typifies the bullish sentiment of some.